Literature DB >> 28848935

The COPD Pipeline XXXV.

Nicholas Gross1.   

Abstract

Year:  2017        PMID： 28848935      PMCID： PMC5556915          DOI： 10.15326/jcopdf.4.3.2017.0154

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  5 in total

1.  New Therapies for Asthma and Chronic Obstructive Pulmonary Disease.

Authors:  Nicholas J Gross; Peter J Barnes
Journal:  Am J Respir Crit Care Med       Date:  2017-01-15       Impact factor: 21.405

2.  Low-Volume Whole-Body Vibration Training Improves Exercise Capacity in Subjects With Mild to Severe COPD.

Authors:  Marc Spielmanns; Tobias Boeselt; Rainer Gloeckl; Anja Klutsch; Henrike Fischer; Henryk Polanski; Christoph Nell; Jan H Storre; Wolfram Windisch; Andreas R Koczulla
Journal:  Respir Care       Date:  2016-12-06       Impact factor: 2.258

3.  Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic Obstructive Pulmonary Disease.

Authors:  Peter M A Calverley; Kay Tetzlaff; Claus Vogelmeier; Leonardo M Fabbri; Helgo Magnussen; Emiel F M Wouters; William Mezzanotte; Bernd Disse; Helen Finnigan; Guus Asijee; Christoph Hallmann; Henrik Watz
Journal:  Am J Respir Crit Care Med       Date:  2017-11-01       Impact factor: 21.405

Review 4.  Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.

Authors:  Aaron M Mulhall; Christopher A Droege; Neil E Ernst; Ralph J Panos; Muhammad A Zafar
Journal:  Expert Opin Investig Drugs       Date:  2015-09-30       Impact factor: 6.206

5.  The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia.

Authors:  Mark J Turner; Elizabeth Matthes; Arnaud Billet; Amy J Ferguson; David Y Thomas; Scott H Randell; Lawrence E Ostrowski; Kathy Abbott-Banner; John W Hanrahan
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-11-06       Impact factor: 5.464
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.